A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Other: Serum and plasma samples analysis
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 42
- Registration Number
- NCT04268628
- Locations
- 🇧🇷
Sociedade Beneficiante de Senhoras - Hospital Sirio Libanes, São Paulo, Brazil
A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1
Completed
- Conditions
- HIV
- Interventions
- Drug: Antiretroviral Therapy
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 105
- Registration Number
- NCT04147325
- Locations
- 🇵🇹
Chlo - Hosp. Egas Moniz, Lisboa, Portugal
A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Oral Antipsychotics (OAPs)
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 55
- Registration Number
- NCT03666715
- Locations
- 🇵🇹
Neurobios , Instituto De Neurociências, Porto, Portugal
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- B-cell Chronic Lymphocytic Leukemia
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Registration Number
- NCT02437019
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 142
- Registration Number
- NCT01448720
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Registration Number
- NCT01026376
A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 223
- Registration Number
- NCT01010776
The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 22
- Registration Number
- NCT00814658
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Phase 4
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2013-07-23
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 60
- Registration Number
- NCT00783835
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol
Phase 4
Completed
- Conditions
- Contraception
- Interventions
- Drug: Norelgestromine (NLGM)/ethinyl estradiol (EE)
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 580
- Registration Number
- NCT00307632
© Copyright 2025. All Rights Reserved by MedPath